Atlas Venture Fund XII L.P. 13D and 13G filings for Aerovate Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-12-15 4:06 pm Sale | 2022-12-12 | 13D | Aerovate Therapeutics, Inc. AVTE | Atlas Venture Fund XII L.P. | 2,039,249 8.300% | -304,180 (-12.98%) | Filing |
| 2022-07-20 4:22 pm Sale | 2022-07-15 | 13D | Aerovate Therapeutics, Inc. AVTE | Atlas Venture Fund XII L.P. | 2,343,429 9.600% | -304,180 (-11.49%) | Filing |
| 2022-05-05 4:04 pm Purchase | 2022-04-01 | 13D | Aerovate Therapeutics, Inc. AVTE | Atlas Venture Fund XII L.P. | 2,647,609 10.800% | 2,647,609 (New Position) | Filing |